Details of the Drug Combination

General Information of Drug Combination (ID: DC38HON)

• Drug Combination Name: Rituximab + Iboctadekin
• Indication: Follicular lymphoma; Non-hodgkin lymphoma; Atrial fibrillation; Status: Phase 1 [1]
• Component Drugs:
  Rituximab (DM1YVZT): Antibody
  Iboctadekin (DMHS29U): N.A.

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Rituximab

Disease Entry	ICD 11	Status	REF
Central nervous system non-hodgkin lymphoma	N.A.	Approved	[2]
Eosinophilic granulomatosis with polyangiitis	4A44.A2	Approved	[3]
Hepatosplenic T-cell lymphoma	N.A.	Approved	[4]
Idiopathic thrombocytopenic purpura	3B64.10	Approved	[5]
Large granular lymphocytic leukemia	2A90.1	Approved	[6]
Leukemia	N.A.	Approved	[7]
Lupus nephritis	4A40.0Y	Approved	[8]
Lymphoproliferative syndrome	N.A.	Approved	[9]
Lymphosarcoma	N.A.	Approved	[10]
MALT lymphoma	N.A.	Approved	[11]
Nodal marginal zone lymphoma	2A85.0	Approved	[12]
Non-hodgkin lymphoma	2B33.5	Approved	[13]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[14]
Prolymphocytic leukaemia	2A82.1	Approved	[15]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[16]
Small intestine lymphoma	N.A.	Approved	[17]
Small lymphocytic lymphoma	2A82.0	Approved	[18]
Splenic marginal zone lymphoma	N.A.	Approved	[19]
Testicular lymphoma	N.A.	Approved	[20]
Thrombotic thrombocytopenic purpura	3B64.14	Approved	[21]
Waldenstrom macroglobulinemia	2A85.4	Approved	[22]
Pemphigus vulgaris	EB40	Phase 3	[23]
Haematological malignancy	2B33.Y	Phase 1	[24]
B-cell neoplasm	N.A.	Investigative	[25]

Rituximab Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	.	[27]
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	.	[28]

Rituximab Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases ADR	[29]
Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)	OTOWXCF3	FCG3A_HUMAN	Increases Response	[30]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases ADR	[29]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases ADR	[29]

Indication(s) of Iboctadekin

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1	[26]
Ovarian cancer	2C73	Phase 1	[26]

Iboctadekin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Interleukin-18 (IL18)	TTRICUF	IL18_HUMAN	Modulator	[31]

References

• [1] FDA Drug Development and Drug Interactions
• [2] How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
• [3] Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
• [4] Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
• [5] Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
• [6] Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
• [7] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
• [8] 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
• [9] Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
• [10] Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
• [11] Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
• [12] Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [14] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [15] B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
• [16] Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023 Mar;64(3):586-596.
• [17] Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
• [18] Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
• [19] Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
• [20] First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
• [21] Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536.
• [22] Waldenstr?m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-358.
• [23] ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
• [25] Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008435)
• [27] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [28] Clinical pipeline report, company report or official report of Genentech (2009).
• [29] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [30] FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11.
• [31] Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.